Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.
Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.4.3 was added and the previous revision v3.4.2 was removed.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.4.2 was added; the page removed the government funding lapse notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check39 days agoChange DetectedA site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and transactions may not be processed, and that the NIH Clinical Center is open; the site version was updated to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check46 days agoChange DetectedThe page now shows the glossary and updates several metadata labels (e.g., Last Update Submitted that Met QC Criteria) with a new revision label v3.4.0, while some legacy labels and capitalization were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check53 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%
- Check82 days agoChange DetectedAdded a new Locations section with California as a listed site and updated the revision from v3.3.2 to v3.3.3. The old California Locations link and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.